New pill combo aims to tame hepatitis d in small trial
NCT ID NCT05229991
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This completed Phase 3 trial tested a once-daily combination of two drugs, lonafarnib and ritonavir, in 10 adults with chronic hepatitis D. The goal was to see if the regimen is safe and can lower the amount of virus in the blood over 48 weeks of treatment and 24 weeks of follow-up. Because the study is very small, the results are preliminary and need confirmation in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey
Istanbul, Turkey (Türkiye)
-
New Zealand Liver Transplant Unit, Auckland City Hospital
Auckland, New Zealand
-
Soroka UMC
Beersheba, Israel
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lonafarnib and ritonavir
What this could lead to
If it works, this could offer a simpler once-daily pill regimen to control hepatitis D virus levels in patients with chronic infection.
What could go wrong
This is a very small, early-phase trial with only 10 participants, so results may not apply broadly. The drug combination may not effectively lower the virus or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.